14.1345  0.365 (2.65%)		10-24 16:00
Open: 13.95 High: 14.21 Volume: 24,377		Pre. Close: 13.77 Low: 13.56 Market Cap: 29(M)

Short term
Mid term
Targets	6-month :	17.09	1-year :	19.97
Resists	First :	14.64	Second :	17.09
Pivot price	13.66
Supports	First :	13.07	Second :	12.1
MAs	MA(5) :	13.3	MA(20) :	13.73
	MA(100) :	12.77	MA(250) :	14.96
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	54.9	D(3) :	37.1
RSI	RSI(14): 55.3
52-week	High :	22.9	Low :	8.73

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CVKD ] has closed below upper band by 25.1%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.23 - 14.29	14.29 - 14.34
Low:	13.42 - 13.48	13.48 - 13.54
Close:	14.03 - 14.13	14.13 - 14.23

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Sat, 27 Sep 2025
Cadrenal therapeutics (CVKD) CEO Pham sells $131,779 in stock By Investing.com - Investing.com Australia

Fri, 26 Sep 2025
Szot, CFO of Cadrenal, sells $174k in CVKD stock - Investing.com

Mon, 11 Aug 2025
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Business Wire

Thu, 08 May 2025
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - Business Wire

Thu, 13 Mar 2025
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - Stock Titan

Tue, 20 Aug 2024
CVKD Stock Touches 52-Week High at $6.03 Amid Market Fluctuations - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	26.6 (%)
Held by Institutions	7.2 (%)
Shares Short	10 (K)
Shares Short P.Month	11 (K)

EPS	-8.89
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.14
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-157.5 %
Return on Equity (ttm)	-340.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-7.02
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-1.6
PEG Ratio	0
Price to Book value	6.6
Price to Sales	0
Price to Cash Flow	-2.49

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.